Construction and mechanism of single-dose, dry-powder inhalation vaccine
CREDIT: Image by MA Guanghui’s group
Researchers develop a novel dry-powder inhaled vaccine platform
Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences have proposed a new “nano-micro composite” delivery concept for vaccines. Based on this idea, they have developed a single-dose, dry-powder, inhalable vaccine platform using nano-micro composite multilevel structures, which has been successfully prepared in the laboratory, and the vaccine has been shown to be effective in blocking respiratory viral infection and transmission in animal models. This platform holds great promise for combating future emerging and epidemic infectious diseases.
This study was published in Nature on Dec 13.
In recent years, researchers have made significant progress in developing vaccines for infectious respiratory diseases. However, most of these vaccines are administered through intramuscular injection, which primarily induces a humoral immune response and relies on blood antibodies to neutralize the virus. Unfortunately, this approach fails to trigger a mucosal immune response and establish a robust immune barrier in the respiratory tract.
Moreover, adjuvants commonly used in current vaccines, e.g., aluminum adjuvants, are unable to induce cellular immune responses and are ineffective in combating rapid viral mutations. Additionally, the current liquid form of vaccines necessitates strict low-temperature storage conditions, and the two- or three-dose vaccination schedule also impacts the overall vaccination rate.
To address these problems, interdisciplinary integration and innovative research concepts are needed to develop safer and more efficient vaccines for respiratory infections.
Taking this approach, Prof. WEI Wei and Prof. MA Guanghui, from the State Key Laboratory of Biochemical Engineering at IPE, in cross-disciplinary collaboration with Prof. WANG Hengliang and Prof. ZHU Li, from the State Key Laboratory of Pathogen and Biosecurity, have developed a new vaccine platform to tackle these challenges.
This platform combines biodegradable microspheres with protein nanoparticles. The surface of these nanoparticles can simultaneously display multiple antigens, thus inducing a broad-spectrum immune response and expanding the range of vaccine protection. It also allows for the quick and convenient development of other respiratory virus vaccines due to the flexibility of antigen presentation.
Moreover, the platform’s unique nano-micro composite structure enables an efficient immune response in the lungs by facilitating high-performance delivery. Once the antigen-nanoparticles are released, they can be efficiently taken up by antigen-presenting cells.
Additionally, this dry powder vaccine significantly reduces storage and transportation costs, making it suitable for areas with limited refrigeration facilities, thus improving immunization rates.
Furthermore, the sustained release of antigens in the vaccine induces long-lasting humoral, cellular, and mucosal immunity with just a single inhalation. In later cooperation with Prof. HE Zhanlong of the Institute of Medical Biology of the Chinese Academy of Medical Sciences, the researchers developed a model of airborne protection, close contact protection, and airborne transmission blocking, which described the benefits of inhaled vaccine for preventing the virus infection and transmission.
“The components of this nano-micro system used natural proteins and approved polymer materials, and the effectiveness and safety of the vaccine have been systematically studied in non-human primates, indicating its great potential for clinical translation.” said Prof. WEI Wei.
Original Article: Researchers develop a novel dry-powder inhaled vaccine platform
More from: Chinese Academy of Sciences
The Latest Updates from Bing News
Go deeper with Bing News on:
Dry-powder inhaled vaccine
- Safety and Efficacy of Combined Long-Acting Beta-Agonists and Inhaled Corticosteroids vs Long-Acting Beta-Agonists Monotherapy for Stable COPD
Background: Current guidelines recommend the use of inhaled corticosteroids (ICSs) added to long-acting β 2-agonists (LABAs) for treatment of symptomatic patients with severe and very severe COPD.
- Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
IMPAHCT (Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial) is a global Phase 2b/Phase 3 trial of AV-101, our self-administered, twice daily dry powder inhaled formulation of the ...
- Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Enrollment continues into the ...
- Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Aerovate’s initial focus is on advancing AV-101, its proprietary dry powder inhaled formulation of the drug imatinib for the treatment of patients with PAH.
- Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and ...
Go deeper with Bing News on:
Inhalable vaccine platform
- Could Vaccines Of The Future Be Made With Nanoparticles?
Extremely small particles might help scientists develop vaccines that are stable at room temperature and easier to administer.
- Vaccines News
May 13, 2024 — Birth by C-section more than doubles odds of measles vaccine failure. Researchers say it is vital that children born by caesarean section receive two doses of the measles vaccine ...
- Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker
Novavax said the deal with Sanofi allows it to remove its “going concern” warning, which it first issued last year due to doubts about staying afloat.
- IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollmentTopline results expected ...
- Sanofi keeps Novavax afloat with $1.2B bet on its vaccine platform
Sanofi will partner with the struggling Maryland biotech to co-commercialize its COVID-19 jab Nuvaxovid and develop combination vaccines.